Autolus Therapeutics to Present at the Jefferies 2018 London Healthcare Conference
PR Newswire
LONDON, Oct. 30, 2018
LONDON, Oct. 30, 2018 /PRNewswire/ -- Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the Jefferies 2018 London Healthcare Conference, on November 14, at 10:40 am GMT.
A webcast of the presentation will be available on the investor relations section of the company's website: https://www.autolus.com
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com
Investor contact: | International Media Contact: | U.S. Media Contact: |
S.A. Noonan Communications | JW Communications | Rx Communications Group, LLC |
Susan A. Noonan | Julia Wilson | Paula Schwartz |
+1-212-966-3650 | +44 (0)7818 430877 | + 1-917-322-2216 |
View original content:http://www.prnewswire.com/news-releases/autolus-therapeutics-to-present-at-the-jefferies-2018-london-healthcare-conference-300740077.html
SOURCE Autolus Therapeutics plc
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.